tiprankstipranks
Trending News
More News >

IDT Australia Reports 30% Revenue Growth and Strong Contract Pipeline

Story Highlights
IDT Australia Reports 30% Revenue Growth and Strong Contract Pipeline

Don’t Miss TipRanks’ Half-Year Sale

IDT Australia Limited ( (AU:IDT) ) just unveiled an announcement.

IDT Australia Limited reported a 30% increase in quarterly revenue, reaching $4.1 million, driven by new contract wins and a strong pipeline of potential contracts totaling $62 million. The company experienced significant growth in its Active Pharmaceutical Ingredients vertical, which is expected to positively impact its Advanced Therapies and Specialty Orals segments. Despite global trade uncertainties, IDT’s outlook remains positive, with new contracts and proposals indicating robust future growth opportunities.

More about IDT Australia Limited

IDT Australia Limited (ASX: IDT) is an Australian pharmaceutical manufacturing company located in Boronia, Victoria. The company specializes in developing and producing high potency and high containment pharmaceutical products for both local and international clients. IDT’s facilities are cGMP compliant and regularly audited by the US FDA and Australian TGA. The company offers comprehensive services for new drug development, scale-up, and commercial active drug manufacture, as well as various oral and injectable finished drug dose forms.

Average Trading Volume: 409,634

Technical Sentiment Signal: Sell

Current Market Cap: A$45.49M

For an in-depth examination of IDT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1